Table 3.

Treatment-related adverse events

Treatment-related1	Grade 1-2	Grade 3	Grade 4
Any	22 (100)	15 (68.2)	1 (4.5)
Led to dose reduction2	1 (4.5)	12 (54.5)	1 (4.5)
Led to discontinuation3	1 (4.5)	1 (4.5)	0
Adverse events
Anemia	19 (86.4)	3 (13.6)	0
Thrombocytopenia	4 (18.2)	3 (13.6)	0
Neutropenia	2 (9.1)	2 (9.1)	1 (4.5)
Leukopenia	9 (40.9)	1 (4.5)	0
AST elevation	1 (4.5)	1 (4.5)	0
ALT elevation	1 (4.5)	1 (4.5)	0
Total bilirubin elevation	1 (4.5)	0	0
Blood cholesterol elevation	14 (63.6)	0	0
Blood triglyceride elevation	17 (77.3)	0	0
Serum creatinine elevation	1 (4.5)	0	0
Creatine phosphokinase elevation	1 (4.5)	0	0
Hyperglycemia	9 (40.9)	0	0
Hair loss	8 (36.4)	0	0
Weight loss	2 (9.1)	0	0
Mucositis	9 (40.9)	7 (31.8)	0
Nausea	19 (86.4)	1 (4.5)	0
Vomit	14 (63.6)	1 (4.5)	0
Diarrhea	5 (22.7)	2 (9.1)	0
Fatigue	20 (90.9)	0	0
Dizziness	3 (13.6)	0	0
Peripheral neuropathy	2 (9.1)	0	0
Toxic effects specific to radiotherapy
Neck skin reaction	16 (72.7)	0	0
Pharyngitis	10 (45.5)	0	0
Dry mouth	16 (72.7)	0	0
Deafness	10 (45.5)	1 (4.5)	0
Nasopharyngeal necrosis	1 (4.5)	0	0
Trismus	9 (40.9)	0	0
Immune-related adverse events
Pneumonia	1 (4.5)	0	0
Hypothyroidism	0	0	0
Pruritus	7 (31.8)	1 (4.5)	0
Rash	1 (4.5)	1 (4.5)	0
Capillary hyperplasia	2 (9.1)	0	0

Note: data are n (%), unless otherwise noted.

Abbreviations are as follows: AST, aspartate transaminase; ALT, alanine transaminase.

¹Treatment-related adverse events occurred in at least one patient. No patients had serious treatment-related adverse events.

²Dose reduction of cisplatin and 5-fluorouracil.

³Discontinuation of toripalimab.